Meet Professor V. Craig Jordan, Professor of Breast Medical Oncology and Molecular and Cellular Oncology at MD Anderson Cancer Center, University of Texas, leading light in cancer research, and father of the ground-breaking breast cancer drug tamoxifen.
Ever since he favoured studying pharmacology at university over drumming in a rock band, Jordan focused his efforts into developing a thriving career in endocrine breast cancer research. His current work focuses on how oestrogen-induced apoptosis can help prevent breast cancer recurrence after tamoxifen treatment. Jordan’s numerous scientific merits have led to him receiving many awards, including an OBE for services to international breast cancer research and being appointed Honorary Fellow of the Royal Society of Medicine (UK), Fellow of the Academy of Medical Sciences (UK), and Elected Member of the National Academy of Sciences (US).
Following Jordan’s guest review published in Endocrine-Related Cancer, we spoke to him about his career highlights and asked for his advice to early career researchers.
Q: What has been your proudest professional experience so far?
To date, my proudest experience has been to successfully reinvent ICI 46,474, a failed contraceptive, as tamoxifen, one of the most valuable breast cancer medicines that we have today. Back in the 1970s no one was interested in medicines that did not kill cancer, and early clinical experience with tamoxifen in metastatic breast cancer demonstrated only palliative activity. When our work started, it was chemotherapy that was on the spotlight – it was what was going to cure cancer.
My career development was accelerated by guidance from my mentors Paul Carbone, Bill McGuire, Elwood Jensen, and Harold Rusch; and the success of tamoxifen in the 1980s brought me to the University of Wisconsin, where my Tamoxifen Team discovered Selective Estrogen Receptor Modulators (SERMs). Tamoxifen was the pioneering SERM – there are now five different FDA approved SERMs for multiple indications in women’s health, ranging from treatment and prevention of breast cancer, osteoporosis, alleviation of menopausal symptoms and dyspareunia.
I have personally been delighted at the success of my Tamoxifen Team members, both in academia and the pharmaceutical industry. The development of SERMs was always a team effort, and my election to the National Academy of Science and National Academy of Medicine (and the equivalent in the United Kingdom, Fellow of the Academy of Medical Sciences and Honorary Fellow of the Royal Society of Medicine) is an honour I share with my Tamoxifen Teams. The Tamoxifen Team is on the Wall of Honour at the Royal Society of Medicine in London.
Q: What in your working life are you most passionate about?
First of all, I am and have always been passionate about giving opportunities to the young trainees in my Tamoxifen Teams. “We are in it for life” is our team motto – over the last 40 years team members have had my support, and will continue to have it for the rest of their lives. Secondly, my academic passion is focussing on research that can potentially aid the survival of women with breast cancer. And finally, I have had a 40-year long love affair with the triphenylethylene molecule, the oestrogenic basis of the anti-oestrogen tamoxifen. I continue to have a focused interest on the relationship of SERMs with the oestrogen receptor.
Q: What most excites you about your work and the contribution you can make?
Our work on SERMs and acquired resistance to long-term anti-hormone therapy in breast cancer produced some important surprises of clinical significance. Our study of acquired resistance to tamoxifen in the laboratory resulted in our finding that, following long-term anti-oestrogen treatment (5 years), low concentrations of oestrogen kill breast cancer cells. This has clinical significance in physiology and the treatment of breast cancer, a topic which I recently reviewed in Endocrine-Related Cancer (Jordan, VC, 2015, Endocrine Related Cancer. 22:R1 – R31). Moving to the MD Anderson Cancer Center, University of Texas, provides an opportunity to extend the lives of women with new treatment strategies following the diagnosis of breast cancer. These are exciting times as it is clear that around the world our knowledge of breast cancer is accelerating. We must know our enemy in order to destroy it!
Q: What is the best feedback or advice you have ever received?
Early in my career there were two memorable moments where individuals changed my perspective.
I was not a good student during grammar school. I had one interview at Leeds University, Department of Pharmacology, and was lucky to get into university in 1965. My goal was to use organic chemistry to develop drugs to treat cancer. However, a year into my degree I was uncertain I was doing the right courses to get into cancer research. I was then interviewed by Dr Mogey, who was to decide on my change of course. My meeting with Dr Mogey did not go well – he chose to give me honest feedback. He looked at my poor performance to date, stared at me over his half-moon glasses, and said “I don’t think you are good enough to transfer”. In response, I stood up and announced that I would become top of the third year organic chemistry course I was then doing, get a first class pass in biochemistry, and pass my physics course despite the fact I had never taken physics before. I stormed off and narrowly missed smashing his glass door as I slammed it. At that point I learned that either you chose to fight, or you fold. I chose to fight, but not to transfer courses because of my love of chemistry.
Years later I discovered two things about Dr Mogey. Firstly, he recommended me for a prestigious Ackroyd scholarship, which I won for my exam performance in my first year at Leeds. Secondly, he wrote a letter of recommendation for me to become a faculty member in his pharmacology department. Thanks to Dr Mogey’s feedback, I learned the qualities that it took to be an honest and good faculty member, and how to fight to succeed in a chosen path.
Similarly, when I was a visiting scientist at the Worcester Foundation in 1974, a Dr Eliahu Caspi called me into his office for an interview to decide, based on documented performance, whether I was to be offered a job there and not return to England. At the interview, he picked up my CV, glowered at me over his desk and stated “you don’t have a CV, because you haven’t published anything”. This hammer blow was another Mogey moment. I replied that I couldn’t publish because I had still not discovered anything. His advice then was to tell the story so far; to connect my publications together so that I could have a theme – and this became my working model.
Q: Based on your experience, what qualities or skills do you feel young scientists need to be successful?
I believe there are two essential skills that every young person must master. Firstly, without the ability to stand up and give a presentation you cannot communicate with your colleagues. Secondly, it is fundamental that you become encyclopaedic about your topic of research. The postdoctoral fellows of my current Tamoxifen Team at the MD Anderson Cancer Center are required to present historical papers from past Tamoxifen Teams – not only to hone their presentation skills, but also to learn about the development of models that we have created in the past and still use for our experiments today. After six months of presentations, I consider these trainees to be fully prepared to go into scientific meetings with enough confidence and a sound background of relevant knowledge.
Q: What advice would you give early-career researchers when thinking about publishing their work?
We return to Dr Caspi, who we met earlier in this interview and who advised me to publish. I echo his advice – if you do not publish the results you have found and tell the story so far, you have never done the work. If it’s not in print, it never happened; and you cannot claim primacy of an idea.
Every ambitious young person first wants to publish in Nature or the Proceedings of the National Academy of Sciences, which I don’t think is a good plan to start with – it helps the mentor’s reputation, not the young researcher’s. When I returned to the University of Leeds from the Worcester Foundation in 1974, I decided to publish my work in the Journal of Endocrinology, the European Journal of Cancer and, since I was a pharmacologist, the British Journal of Pharmacology. Between 1974 and 1980 I published 11 referred articles in the Journal of Endocrinology. I wanted to create impact for my work on the new anti-cancer drug tamoxifen. In 1975, I attempted to publish three papers on tamoxifen in a single issue of the Journal of Endocrinology, and almost succeeded! So my second piece of advice is to attract attention, and to publish in journals from professional societies. I published my highest cited (445) scientific paper on tamoxifen in the Journal of Endocrinology; a paper that turned out to become the blueprint for all future SERMs over the next decade.
Q: What do you enjoy doing in your spare time?
For me this has always been age dependant. As a young man at Leeds University, between 1966 and 1979, I was an Army Reserve Officer in the Intelligence Corps, and remained with the Special Air Service as a Regular Army Reserve Officer until the age of 55. During the past two decades I have enjoyed the beautiful mountains of the Austrian Tyrol and international travel. During the last decade I have taken much pleasure in my library of 6,000 hardback books and, over the years, in the exchanged correspondence with several of the authors who are soldiers, scientists, TV presenters and one spy.
Q: Who do you admire most and why?
I admire individuals who, against all odds, can achieve success in an activity that advances society.
Dr Margaret Foti is the CEO of the American Association for Cancer Research (AACR), the oldest cancer research organization in the world. She initially joined the AACR as an editorial assistant for their single journal Cancer Research and became the youngest managing editor of a major scientific journal in the country. Under her leadership, the AACR membership has grown from 3,000 to 37,000 with representatives from 108 countries. The journal portfolio has grown from 1 to 8 major scientific journals. She worked for a PhD along the way and was honoured with an MD. Marge is the modern AACR.
Dr Angela H. Brodie died on June 7, 2017. Angela told her students to do research that serves to help mankind. She trained as an endocrinologist and, together with her husband Harry, discovered the first selective aromatase inhibitor. At that time no companies were interested in developing an aromatase inhibitor to treat breast cancer, so Angela did it herself. The medicine was synthesised at the University of Maryland, shipped to England and tested showing positive results. She succeeded when others would not have given battle. Her determination resulted in the development of three FDA aromatase inhibitors and hundreds of thousands of lives saved. Angela had a calm, shy personality, but a will of steel.
Members of the Society for Endocrinology get free online access to the current content of Endocrine-Related Cancer, as well as Journal of Endocrinology, Journal of Molecular Endocrinology and Clinical Endocrinology, via the Members’ Area.
Looking to publish your research? Our members also enjoy no colour or supplementary data charges when publishing in Endocrine-Related Cancer, Journal of Endocrinology and Journal of Molecular Endocrinology. Find out more about member benefits.